revusiran
Nucleic acidexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01814839)
Timeline
Indications
Mechanism of action
- Transthyretin mRNARNAI INHIBITOR
Transthyretin mRNA RNAi inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594492 ↗
Also known as
- revusiran
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02595983 | Phase 2 | Oct 1, 2015 | Alnylam Pharmaceuticals |
| NCT02319005 | Phase 3 | Dec 1, 2014 | Alnylam Pharmaceuticals |
| NCT02292186 | Phase 2 | Oct 1, 2014 | Alnylam Pharmaceuticals |
| NCT01981837 | Phase 2 | Dec 1, 2013 | Alnylam Pharmaceuticals |
| NCT01814839 | Phase 1 | Mar 1, 2013 | Alnylam Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | For profit | 5 | 5 | 3 | 2013 |
1 organizations
Page 1 / 1